Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2018.1524822 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
Vet Dermatol
December 2023
Vet Derm Tokyo, Dermatological and Laboratory Service for Animals, Fujisawa, Japan.
Background: Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO-524 containing PUFA has demonstrated anti-inflammatory effects in dogs.
Hypothesis/objectives: To evaluate the efficacy of PCSO-524, in combination with oclacitinib in dogs with cAD.
Full Breastfeeding and Allergic Diseases-Long-Term Protection or Rebound Effects?
Nutrients
June 2023
Children's Hospital, Evangelisches Krankenhaus Düsseldorf, 40217 Düsseldorf, Germany.
A previous follow-up of the GINIplus study showed that breastfeeding could protect against early eczema. However, effects diminished in adolescence, possibly indicating a "rebound effect" in breastfed children after initial protection. We evaluated the role of early eczema until three years of age on allergies until young adulthood and assessed whether early eczema modifies the association between breastfeeding and allergies.
View Article and Find Full Text PDFA randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
Vet Dermatol
April 2023
Cabinet Vétérinaire, Spa, Belgium.
Article Synopsis
- A study investigated whether a brief 4-day treatment with prednisolone could reduce the chances of pruritus rebound in dogs with atopic dermatitis after decreasing their oclacitinib dosage.
- Forty dogs participated, and results showed that only 15% of those receiving prednisolone experienced a rebound in itchiness, compared to 45% of those on oclacitinib alone.
- The addition of prednisolone improved skin condition assessments and overall treatment satisfaction, with only minor side effects reported.
Contact Dermatitis in Atopic Dermatitis Children-Past, Present, and Future.
Clin Rev Allergy Immunol
February 2019
Department of Dermatology, Loma Linda University, Anderson Street, Suite 2600, Loma Linda, CA, 92354, USA.
Allergic contact dermatitis (ACD) used to be considered a rarity in children, but recently has been estimated to effect 4.4 million children in the USA alone, with a notable rise in investigative research in the field of pediatric ACD. Researchers have shown that patch testing is safe and effective in afflicted children and that those with atopic dermatitis (AD) have similar sensitization rates, although they have a higher sensitization to certain allergens, thought to be related to the inflammatory (IL-4) milieu.
View Article and Find Full Text PDFRebound of atopic dermatitis as a complication of using systemic glucocorticoids; a myth or a fact?
J Dermatolog Treat
June 2019
c Department of Pathology , Wake Forest School of Medicine, Winston-Salem , NC , USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!